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A B S T R A C T
Despite enormous progress in radiation technologies (high precision image-guided irradiation, proton
irradiation, heavy ion irradiation) and radiotherapeutic concepts (hypofractionated irradiation schemes),
the clinical outcome of radiotherapy in locally advanced and metastasized tumors and in hypoxic tumors
which are radiation-resistant remains unsatisfactory. Given their key inﬂuence on a number of biolog-
ical and immunological parameters, this article considers the inﬂuence of irradiation-induced stress proteins
on radiation-induced immunomodulation. Depending on its location, themajor stress-inducible Heat shock
protein 70 (Hsp70) has been found to fulﬁll multiple roles. On the one hand, increased intracellular Hsp70
levels have been found to play a key role in the recovery from stress such as radio(chemo)therapy, and
on the other hand extracellular Hsp70 proteins are potent stimulators of the innate immune system and
mediators of anti-tumor immunity. Furthermore, if loaded with tumor-derived peptides, members of the
Heat Shock Protein 70 (HSP70) and 90 (HSP90) families can stimulate the adaptive immune system via
antigen cross-presentation. An irradiation-induced enhancement of the selective expression of a mem-
brane form of Hsp70 on the surface of tumor cells which can act as a recognition structure for activated
NK cells might have signiﬁcant clinical relevance, in that the outcome of irradiation therapy for ad-
vanced tumors could be improved by combining it with cell-based and other immunotherapies that target
this membrane form of Hsp70.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Major stress-inducible Heat Shock Protein 70 (Hsp70):
function and subcellular localization
Heat Shock Proteins (HSPs) were ﬁrstly described by Ferruccio
Ritossa in 1962 [1] as a set of evolutionary highly conserved genes
in Drosophila melanogaster that are activated upon heat stress. Six
of the eight members of the HSP70 family predominantly reside in
the cytosol, where they maintain protein homeostasis by support-
ing the folding, refolding, and assembly of nascent polypeptides,
preventing protein aggregation, and assisting the transport of other
proteins across membranes [2]. Apart from heat, the synthesis of
different HSP family members is increased by a large variety of
different stressors including chemo- and radiation therapy which
cause the production of reactive oxygen species (ROS) and also during
cell proliferation and differentiation. A comparison of two highly
homologous members of the HSP70 family, the constitutive Hsc70
(Hsp73, HSPA8, Hsp70-8) and the major stress-inducible Hsp70
(Hsp72, HSPA1A, Hsp70-1), has revealed that, under physiological
conditions, the constitutive Hsc70 is expressed at higher levels than
Hsp70, whereas the synthesis of Hsp70 is more rapid and accumu-
lates in different subcellular compartments after stress [3,4].
Furthermore, in contrast to normal cells, tumors frequently
overexpress Hsp70 in the cytosol, present Hsp70 on their plasma
membrane [5,6], and actively release Hsp70 [7–9]. Elevated cyto-
solic levels of Hsp70 and Hsp27 have been found to mediate
protection against apoptosis, promote malignant transformation, se-
nescence and metastatic spread [10–15], whereas extracellular,
tumor-derived HSPs are considered to act as danger signals [16] that
can elicit anti-tumor immune responses [13,17–19]. A summary of
the key actions of Hsp70 depending on their localization is shown
in Table 1.
Membrane localization of Hsp70 on tumor cells is enabled
by tumor-speciﬁc lipid components. Under physiological
conditions Hsp70 co-localizes with the lipid raft glycolipid
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globoyltriaosylceramide (Gb3) [27], whereas Hsp70 is predomi-
nantly associated with phosphatidylserine (PS) outside of lipid
rafts after stress. In non-stressed cells, the ATP-dependent
aminophospholipid translocase [28] enables the exclusive localiza-
tion of PS to the inner side of the plasma membrane. However, PS
translocates from the inner to the outer plasma membrane leaﬂet
via an activation of the ATP and Ca2+ dependent phospholipid
scramblase after stress and thus provides an early marker of apop-
tosis [29]. Although the role of PS in the outer membrane leaﬂet is
still not completely clear, it is assumed that oxidatively modiﬁed PS
provides a phagocytic “eat-me” signal [30]. However, PS positivity
does not necessarily mean that cells are no longer viable, as Hsp70/
PS membrane-positive tumor cells are viable and can be grown in
cell culture [31,32]. Furthermore, viable T cells also have been found
to present PS on the outer leaﬂet following activation [33].
HSPs as targets for adaptive and innate immune responses
The potential of using members of families (particularly the
70 kDa and 90 kDa families) as potential chaperones for immuno-
genic peptides in the context of cancer immunotherapeutics has
been considered by the group of Srivastava for many years [18].
Although the clinical success of this approach has been variable,
the use of tumor-derived gp96 has been introduced into the clin-
ical setting (Prophage Series of vaccines from Agenus:
www.agenus.com/science/prophage.php). These studies were based
in the concept that isolated from tumor tissue chaperoned tumor-
speciﬁc peptides and, on administration, could induce the generation
of peptide-speciﬁc effector cells. The speciﬁcity of the immunity
that was generated was reported as being toward the antigenic
peptides that were carried by the HSP, rather than the HSP itself.
It was therefore proposed that this avoided potential cross reac-
tivity with other tissues expressing the relevant. Some subgroups
responded very well, whereas others have not proﬁted from the
therapy. Potential problems with this approach involved the limited
amount of tissue from which the HSP (and therefore the vaccine)
could be generated. Notwithstanding this, a number of clinical trials
evaluating the clinical potential approach have been performed,
and some success has been obtained [34]. As with all such studies,
the translation of such therapies has been slow due to the fact
that initial clinical trials are usually performed in patients with
advanced disease.
Furthermore, the search for tumor-speciﬁc targets which are
located intracellularly in normal cells, but are expressed on the cell
surface of tumor cells and can be recognized by immune compe-
tent effector cells, has resulted in the identiﬁcation of such as Hsp70,
Hsp90, or Grp78 [35]. Herein, we concentrate on the major stress-
inducible Hsp70 which is exclusively expressed on the cell surface
of tumor cells, but not normal cells [5]. Ionizing irradiation, even
at sublethal doses (below 5 Gy), induces the synthesis of Hsp70 in
the cytosol of normal and tumor cells [36]. However, due to differ-
ences in the lipid composition of the plasmamembrane only tumor
cells have the capacity to present Hsp70 on their cell surface [27].
Irradiation as well as other stress factors such as heat, chemothera-
peutic agents, Hsp90 inhibitors, amino acid analogues, glucose
deprivation, hypoxia and reoxygenation, and drugs [37] further in-
creases the cell surface density of Hsp70 on tumor cells. The cell
surface bound form of Hsp70 on viable tumor cells is detectable using
a mouse monoclonal antibody (cmHsp70.1, patent multimmune
GmbH) [38], but not by other commercially available Hsp70-
speciﬁc antibodies. The cmHsp70.1 monoclonal antibody (mAb)
antibody detects the conformation of Hsp70 in the plasma mem-
brane of tumor cells and does not cross-react with the highly
homologous Hsc70.
Low dose irradiation up-regulates a number of immunologically-
relevant antigens, such asmajor histocompatibilitymolecules (MHC),
tumor-associated antigens (Carcinoembryonic Antigen (CEA)), mucin
1 [39], as well as the expression of the Intercellular Adhesion
Molecule-1 (ICAM-1) on endothelial cells [40] and the apoptosis
inducer Fas (CD95), all of which have immunomodulatory proper-
ties [41,42]. In addition to the direct killing of cancer cells by ionizing
irradiation which is mediated by DNA damage can also induce non-
targeted abscopal or bystander effects that can elicit the stimulation
of T and NK cell mediated immune responses [42]. Most of these
antigens are also relevant for the induction and regulation of T cell
mediated immune responses and the generation of protective anti-
tumor immunity [43]. T cells can be roughly grouped into CD4+ T
helper cells that recognize antigenic determinants presented byMHC
class II molecules on antigen presenting cells (APCs), and CD8+ cy-
totoxic T cells which recognize their target antigenic peptides that
are presented in the context of MHC class I molecules [44]. CD4+ T
helper cells exist in different epigenetic states such as Th1, Th2, Th17,
fork-head box 3 (Foxp3+) T regulatory cells, T follicular helper, Th9,
and Th22 cells [45] that are determining their different functions.
Th17 cells show a high plasticity and thus can acquire pro-
inﬂammatory characteristics of Th1 cells. T cells recognize MHC–
peptide complexes via clonal T cell receptors which exhibit an
enormous heterogeneity which is generated by variable diversity
joining gene recombination and crossover events. T cell mediated
immune responses, and the memory which they display, play a
crucial role in immunosurveillance of cancer. However, effective anti-
cancer immune responses can be blocked or down-regulated by
regulatory T (Treg) cell populations which can be characterized, in
part at least, on the basis of their expression of FoxP3 transcrip-
tion factor, a high constitutive cell surface expression of the IL-2
receptor alpha chain (CD25), expression of the glucocorticoid induced
TNF-receptor related protein GITR and the cytotoxic T lymphocyte
associated antigen 4 (CTLA-4), as well as low levels of the IL-7 re-
ceptor (CD127) in humans [46]. Another level of control of anti-
cancer immunity – so called “checkpoint inhibitors” – is also
currently attracting a lot of attention. Under normal circum-
stances, immune checkpoints are important for maintaining self-
tolerance by preventing autoimmunity and protecting the tissue from
damage when the immune system is activated. However, it is now
apparent that the expression of immune checkpoint proteins can
be used to establish resistance mechanisms by tumor cells, thus al-
lowing progressive tumor growth [47]. Attention has therefore turned
to the potential therapeutic value of antibodies that target CTLA-4
and the programmed cell death protein 1/programmed cell death
protein 1 ligand (PD1/PD-L1) to block such interactions and inhibit
this protective response [48–50]. Immune checkpoint blockade is
believed to have enormous therapeutic potential and integrative im-
munotherapies that incorporate immune checkpoint blockade should
result in durable clinical responses and increased cure rates [51].
Table 1
Key actions of Heat shock protein 70 (Hsp70).
Localization Function References
Cytosolic Binds to polypeptides in an ATP dependent
manner
Prevents aggregation of unfolded peptides and
transports proteins
Regulates intercellular signaling
Mediates antigen cross-presentation
[20]
[21]
[18]
Membrane-
bound
Acts as a tumor-speciﬁc recognition structure for
activated NK cells on plasma membranes
Mediates anti-apoptotic functions on lysosomal
membranes
[22]
[10]
Extracellular
free and
lipid-bound
Induces inﬂammatory and anti-inﬂammatory
responses
[23]
[24]
[25]
[26]
180 G. Multhoff et al./Cancer Letters 368 (2015) 179–184
Two major antibody-based therapies are directed against the PD-
1/PD-L1 (Pembrolizumab, Nivolumab) and the CTLA-4 (Ipilimumab)
pathway. Early results are showing impressive response rates in ad-
vanced melanoma patients with manageable toxicity proﬁles.
Myeloid-derived suppressor cells (MDSCs) are key elements of
the cancer-related inﬂammation with potential to support tumor
growth, invasion andmetastatic spread [52]. Apart fromMDSCs, also
T cell derived subpopulations such as CD3+CD56+ double-positive
natural killer T (NKT cells) and CD11b+Gr1+ NK cells that are known
to support tumor control can also exert a negative impact on the
generation of protective anti-cancer immunity [53].
NK cells are a part of the innate immune system which is re-
sponsible for the ﬁrst line of defense against viral and bacterial
infections, as well as malignantly transformed cells and tumors. In
a similar way to T cells, NK cell subpopulations have a number of
immunoregulatory functions and can kill their targets via the se-
cretion of interferon gamma (IFNγ), tumor necrosis factor alpha
(TNFα) and T cell recruiting chemokines (RANTES, MIP1α, MIP1β),
and the induction of apoptosis via Fas–Fas ligand and TRAIL–
receptor interactions, and the release of granzyme B and perforin
[54–61]. The recognition of the Fc component of antibodies which
have bound to tumor-speciﬁc or tumor-associated antigens by NK
cells triggers antibody-dependent cellular cytotoxicity (ADCC), and
thereby establishes a link between B cell and NK cell-mediated
immune responses. In contrast to T cells, NK cells do not express a
single clonal receptor type rather they express a large variety of dif-
ferent receptors on one cell. The balance between the expression
density of activating receptors with a short immunoreceptor
tyrosine-based activation motif and inhibiting receptors with a long
intracellular tyrosine-based inhibition motif determines whether
an NK cell exerts a cytolytic or inhibitory function. NK cell recep-
tors can be grouped into different families – the immunoglobulin
like, C-type lectin (NKG2D, CD94, NKG2A, NKG2C) and natural cy-
totoxicity (NKp30, NKp44, NKp46) receptors [62]. Membrane Hsp70
serves as a target for activatory C-type lectin NK cell receptors [63].
As indicated above, and in contrast to T cells, pre-activated NK
cells have the capacity to recognize membrane-bound Hsp70 on
tumor cells even in the absence of immunogenic peptides [64]. We
have been able to demonstrate that an incubation of NK cells with
Hsp70 protein or an Hsp70-derived peptide (TKD) plus low dose
interleukin-2 (IL-2) for 3–5 days [65] can stimulate the prolifera-
tive and migratory capacity of NK cells toward highly aggressive
Hsp70 membrane-positive tumor cells [22,66]. We have also shown
that it can initiate apoptotic cell death in these tumor cells via an
increased secretion of granzyme B. A mammalian glycosylation
pattern has been found to be key for the internalization of granzyme
B into membrane Hsp70 positive tumor cells [40,67–69]. A sche-
matic representation of the stimulation of NK cells with Hsp70
peptide TKD plus low dose IL-2, and also the recognition of Hsp70
membrane-positive tumor cells by pre-activated NK cells, is shown
in Fig. 1. This scheme indicates that Hsp70 can be released either
actively from viable tumor cells in liposomes or from dying cells
as free Hsp70, whichmight exert immunostimulatory functions. The
stimulation of NK cells with TKD/IL-2 is associated with an up-
regulation in the expression density of activatory C-type lectin NK
receptors such as CD94, NKG2C, and NKG2D [63,66,70,71]. Since the
increased expression density of these receptors on NK cells is as-
sociated with increased cytolytic activity, the mean ﬂuorescence
intensity of these markers serves as a surrogate for NK cell cyto-
toxicity. Furthermore, tumor cells that have been irradiated or treated
with drugs [37] and thus exhibit an increased cell surface expres-
sion of Hsp70 [22,72] are lysed signiﬁcantly better by NK cells that
had been stimulated with the pro-inﬂammatory cytokine IL-2 and
the Hsp70 peptide TKD than tumor cells with a lower Hsp70 ex-
pression in vitro [65] and in vivo [73]. In this context, it should be
noted that resting NK cells from patients with cancer showed no
cytolytic activity against irradiated tumor cells (unpublished ob-
servation). Therefore, we speculate that anti-tumor immune
responses against membrane Hsp70 positive tumor cells is selec-
tively mediated by activated effector cells of the innate immune
system.
Promising results demonstrating the capacity of pre-activated
human NK cells to induce the regression of Hsp70 membrane pos-
itive human tumors in immunodeﬁcient mice [73] prompted the
initiation of a phase I clinical trial. In this trial, patients with colorectal
and non-small lung cell cancer (NSCLC) who were refractory to
therapy and exhibiting widespread metastatic disease were treated
with an escalating dose of ex vivo TKD/IL-2 activated, autologous
NK cells [71]. The study showed an excellent tolerability and safety
proﬁle for ex vivo stimulated, autologous NK cells in patients even
after 6 repeated re-infusions of complete leukapheresis products.
Two out of 5 patients showed clinical responses (1 stable disease
and 1 mixed response) after only 4 infusion cycles. Despite the low
patient numbers, this result was not expected since all of the treated
patients had not previously shown any response to standard
radio(chemo)therapies. Based on these ﬁndings, a clinical phase II
proof-of-concept trial involving the administration of ex vivo stimu-
lated, autologous NK cells to patients with NSCLC after
radio(chemo)therapy is initiated in late 2014 (Ms submitted). For
this study, radio(chemo)therapy is administered prior to starting the
immune therapy in order to reduce the tumor mass and increase
the density of Hsp70 expression on the surface of surviving resid-
ual tumor cells.
As indicated earlier, membrane Hsp70 positive tumor cells can ac-
tively release Hsp70 in lipid vesicles termed exosomes [66]. As the
amount of liposomal Hsp70 is much higher than that of free Hsp70
which is derived from dying cells (Fig. 1), it was proposed that serum
levels of liposomal Hsp70 might predict the presence of Hsp70
membrane-positive tumors, in vitro. Mouse studies have indicated that
serum Hsp70 levels could correlate with the tumor volume and that
an irradiation-induced tumor regressionwas associatedwith a reduc-
tion in Hsp70 serum levels [74]. These ﬁndings have now been
conﬁrmed in patients with hepatocellular carcinomas (HCC) [9].
liposomal Hsp70
free Hsp70  
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Recognition of Hsp70+
tumor cells by TKD/IL-2 
activated NK cells
Fig. 1. NK cell stimulation with TKD/IL-2. Schematic representation of the ex vivo
stimulation of patient-derived NK cells with Hsp70-peptide TKD plus low dose IL-2
(large red triangles) and recognition of membrane Hsp70 positive tumor cells. Upon
stimulation, the density of activatory C-type lectin receptors (black symbols on NK
cells) such as CD94, NKG2C, NKG2D is upregulated on NK cells. These receptors
mediate recognition of membrane Hsp70 on tumor cells, which resides in lipid rafts.
Hsp70 is transported from the cytosol to the plasma membrane (double-headed
arrow) in tumor cells via a non-ER/golgi transport pathway. Hsp70 can be actively
released by viable tumor cells that express Hsp70 on their plasmamembrane in lipid
vesicles (small circles with small red triangles). Free Hsp70 (small red triangles) is
released by dying tumor cells. In general the amount of liposomal Hsp70 from viable
tumor cells in the extracellular milieu is much higher than that of free Hsp70 which
is released by dying cells. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
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Importantly, these studies have shown that Hsp70 levels are signiﬁ-
cantly higher in the serum of tumor patients compared to healthy
individuals and patients with inﬂammatory diseases such as chronic
hepatitis. We therefore propose that serum Hsp70 levels will provide
a useful biomarker and a minimally invasive approach for predicting
the presence of tumors and for monitoring the outcome of a therapy
in the near future.
In addition to acting as a target recognition structure for acti-
vated NK cells, Hsp70 can act as a vehicle for the delivery of antigenic
peptides to T cells via indirect antigen presentation pathways. It is
generally accepted that the primary sequences of HSP70 and HSP90
proteins are unable to activate a T cell-mediated immune re-
sponse. However, it has been shown that members of the HSP70
and HSP90 family have the capacity to bind immunogenic tumor
peptides that can be cross-presented on MHC molecules of APCs
[75]. Tumor mouse models have revealed that HSP–peptide com-
plexes isolated from tumor cells, but not those isolated from normal
cells, can elicit protective T cell mediated immunity against the same
type of tumor fromwhich the HSP–peptide complexes were derived
[76]. This concept has also been tested in phase I–III clinical trials
in patients with cancer and infectious diseases [77], advancedmela-
nomas [78,79], metastatic colorectal cancer [80], and non-Hodgkin
lymphomas [81,82]. The results of the HSP–peptide vaccination trials
revealed biological responses such as immune stimulation of T cells
and some clinical responses in certain tumor subgroup analyses.
Inhibition of HSP with molecular weights of 90 kDa can induce
immunomodulatory activities. Hsp90 inhibition leads to a com-
pensatory increase in cytosolic Hsp70 levels which reduces the anti-
tumor capacity of the Hsp90 inhibitor and induces a release of Hsp70
from tumor cells (unpublished observation). This concept has re-
cently been reviewed by the Garrido group [83]. It is therefore
important to develop inhibitors of Hsp70 which can be used in com-
bination with the Hsp90 inhibition. At present a number of new
Hsp70 inhibitors that can increase the sensitivity of tumors to ther-
apeutic agents and radiation therapy, and also enhance the eﬃcacy
of established Hsp90 inhibitor strategies, have been tested in pre-
clinical models. Aptamers which bind to the peptide-binding and
ATP-binding domains of Hsp70, and thereby act as Hsp70 inhibi-
tors, have been shown to trigger anti-tumor immune responses and
reduce the growth of subcutaneous B16F10 melanoma tumors in
vivo via a mechanism which is associated with the recruitment of
macrophages and T cells into the tumor bed [84]. Furthermore, a
small molecule inhibitor of Hsp70 (Piﬁthrin-μ) can effectively inhibit
the growth of human prostate cancer cells in vitro, and increase the
anti-tumor effects of hyperthermia in amurine xenograft model [85].
A study by Schlecht and colleagues [86] suggests that the simul-
taneous inhibition of Hsp70 and the constitutive member of the
70 kDa heat shock family, Hsc70, using siRNA approaches is re-
quired in order to reduce the viability of humanMD-MB-468 breast
carcinoma cells. Despite the plethora of roles that Hsp70 has in the
maintenance of cellular homeostasis, Hsp70 inhibitors do not appear
to exhibit toxicity in animals [83–85].
Further to the above, Hsp70 can be directly applied as an anti-
tumor therapeutic. Work of the Margulis group has shown that rat
glioblastomas can be successfully treated with an intratumoral deliv-
ery of exogenousHsp70 [87]. The reduction in tumor size, as conﬁrmed
by magnetic resonance imaging, was associated with a signiﬁcant in-
ﬁltration of tumors byNKandT cells, aswell as an increasedproduction
of granzyme B and interferon-γ.With regard to these promising novel
data frompre-clinical studies, a pilot study in childrenwithbrain tumors
has been initiated. Intratumoral injections of recombinant Hsp70 (up
to ﬁve times) were well tolerated and one patient out of 12 exhibited
a complete clinical response, as documented using radiological imaging
[88]. Immunologically, a shift toward an inﬂammatory Th1 type immune
response was observed in the peripheral blood, as was a reduction in
the prevalence of Treg cells.
Concluding remarks
Despite enormous progress in radiation technologies (high pre-
cision image-guided irradiation, proton irradiation, heavy ion
irradiation), and radiotherapeutic concepts (hypofractionated irra-
diation schemes), the clinical outcome of radiotherapy in locally
advanced and metastasized tumors and in hypoxic tumors which
are radiation-resistant remains unsatisfactory [89–92]. Given their
key inﬂuence on a number of biological and immunological pa-
rameters, this article considers the inﬂuence of irradiation-induced
stress proteins on radiation-induced immunomodulation. It is well
established that, among other stress factors, irradiation initiates the
synthesis of Hsp70 via the production of ROS in eukaryotic cells and
causes the translocation of PS from the inner to the outer plasma
membrane leaﬂet [93,94]. Depending on its location, Hsp70 has been
found to fulﬁll multiple roles. On the one hand, increased intracel-
lular Hsp70 levels have been found to play a key role in the recovery
from stress [2,95] including radio(chemo)therapy. Therefore, in
bladder cancer an inhibition of cytosolic Hsp27 and Hsp70 has been
found to exert beneﬁcial effects for radio(chemo)therapy [96].
On the other hand, membrane-bound and extracellular Hsp70
proteins are potent stimulators of the innate immune system [97].
Fractionated radiation (5 × 2 Gy) enhances the release of Hsp70 from
dying tumor cells and thus stimulates immune responses that are
mediated by NK cells and dendritic cells [78,98]. When loaded with
tumor-derived peptides, members of the HSP70 and HSP90 fami-
lies also have been shown to stimulate the adaptive immune system
via antigen cross-presentation [75–77]. Furthermore, intratumorally
applied Hsp70 initiates immune stimulation in patients with brain
tumors [87], and the eﬃcacy of radiotherapy and intratumoral den-
dritic cell therapy in CT26 tumor mouse models has been shown
to be boosted by a co-injection with recombinant Hsp70 [99].
Although themechanism bywhich Hsp70 is exported is not com-
pletely understood, several laboratories have reported on an active
release of Hsp70 from cultured viable cells into the supernatant,
and this is predominantly in the context of lipid vesicles
[97,100–102]. An alternative vesicular pathway for the export of
Hsp70 that does not involve the classical ER Golgi compartment has
been proposed for the export of liposomal Hsp70 [103]. These ﬁnd-
ings are in line with other groups who demonstrated that inhibitors
which perturb ER Golgi transport, including brefeldin A or monensin
do not affect extracellular Hsp70 release [104]. It has been shown
that environmental stress, including fractionated irradiation, causes
a translocation of Hsp70 from the cytosol into the extracellular
milieu, where it can stimulate the innate immune system in the pres-
ence of pro-inﬂammatory cytokines [6]. Furthermore, Hsp70 has
been found to co-localize with PS in the outer membrane leaﬂet of
stressed tumor cells [32], whereas PS is restricted to the inner plasma
membrane leaﬂet in non-stressed cells [105]. Given that Hsp70 and
PS are co-localized in themembrane of stressed tumor cells, we spec-
ulate that Hsp70 is translocated to the outer membrane leaﬂet by
ﬂipping together with PS during the process of early apoptosis or
by a fusion of Hsp70/PS containing lipid vesicles with the plasma
membrane.
Immunologically, an irradiation-induced enhanced Hsp70 mem-
brane expression on highly aggressive tumor cells could serve as a
recognition structure for activated, but not for resting, NK effector
cells. Taken together, these ﬁndings might have signiﬁcant future
clinical relevance, in that the clinical outcome of irradiation therapy
for advanced tumor diseases could be improved by combining it with
cell-based and other immunotherapies that target membrane Hsp70.
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